Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty

Japanese Circulation Journal

Volumn 60, Issue 4, 1996, Pages 207-215

  Tsutsui, Masato ^a   Shimokawa, Hiroaki ^b   Higuchi, Seiji ^a   Yoshihara, Shingo ^a   Hayashida, Kiyoshi ^a   Sobashima, Atsushi ^a   Kuga, Takeshi ^a   Matsuguchi, Takeyuki ^a   Okamatsu, Shuichi ^a  

^a ASO IIZUKA HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Anti platelet drug; Cilostazol; Percutaneous transluminal coronary angioplasty (PTCA); Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CILOSTAZOL; CYCLIC AMP; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; TICLOPIDINE; TRIACYLGLYCEROL; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RESTENOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONSTRICTION, PATHOLOGIC; CORONARY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TETRAZOLES;

EID: 0029935854     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.60.207     Document Type: Article

References (30)

1. Block PC: Restenosis after percutaneous transluminal coronary angioplasty: anatomic and pathophysiological mechanisms. Circulation 1990; 81(Suppl IV): IV2-IV4
2. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation 1991; 84: 1426-1436
3. Hermans WR, Rensing BJ, Strauss BH, Serruys PW: Prevention of restenosis after transluminal coronary angioplasty: The search for a "magic bullet". Am Heart J 1991; 122: 171-187
4. Bobbio M, Detrano R, Colombo A, Lehmann KG: Restenosis rate after percutaneous transluminal coronary angioplasty: A literature overview. J Invas Cardiol 1991; 3: 214-224
5. Califf RM, Willerson JT: Thrombosis in cardiovascular disorders. In: Fuster V, editor. Percutaneous transluminal coronary angioplasty: Prevention of occlusion and restenosis. Philadelphia: W.B. Saunders Company, 1992; 389-408
6. Liu MW, Roubin GS, King III SB: Restenosis after coronary angioplasty: Potential biologic determinants and role of intimai hyperplasia. Circulation 1989; 79: 1374-1387
7. Nishi T, Tabusa F, Tanaka T, et al: Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II: 6-[3-(1-Cyclohexyl-5-tetrazolyl) propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull 1983; 31: 1151-1157
8. Hladovec J: Is the antithrombotic activity of "anti-platelet" drugs based on protection of endothelium? Thromb Haemost 1979; 41: 774-778
9. Ashida S, Abiko Y: Mode of action of ticlopidine in inhibition of platelet aggregation in the rat. Thromb Haemost 1979; 41: 436-449
10. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung/Drug Res 1985; 35: 1144-1149
11. Ikeda Y, Kikuchi M, Murakami H, et al: Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo: Randomized, double-blind cross-over study. Arzneimittelforschung/Drug Res 1987; 37: 563-566
12. Saitoh S, Saito T, Otake A, Owada T, Maruyama Y: Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler Thromb 1993; 13: 563-570
13. Kawamura K, Watanabe K, Kimura Y: Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung/Drug Res 1985; 35: 1149-1154
14. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H: Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988; 36: 313-320
15. Takahashi S, Oida K, Fujiwara R, et al: Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900-906
16. Nobuyoshi M, Kimura T, Nosaka H, et al: Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cordiol 1988; 12: 616-623
17. Umekawa H, Tanaka T, Kimura Y, Hidaka H: Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem Pharm 1984; 33: 3339-3344
18. Friedman G: Modulation of lipoprotein lipase activity in cultured rat mesenchymal heart cells and preadipocytes by dibutyryl cyclic AMP, cholera toxin and 3-isobutyl-1-methylxanthine. Biochim Biophys Acta 1983; 752: 106-117
19. Maziere C, Mazierc J, Salmon S, Auclair M, Mora L, Polonovski J: Cyclic AMP decreases LDL catabolism and cholesterol synthesis in the human hepatoma cell line Hep G2. Biochem Biophys Res Commun 1988; 156: 424-431
20. Califf RM, Ohman EM, Frid DJ, et al: Textbook of interventional cardiology. In: Topol EJ, editor. Restenosis: The clinical issues. Philadelphia: W.B. Saunders Company, 1990; 363-394
21. Bourassa MG, Lesperance J, Eastwood C, et al: Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991; 18: 368-376
22. Gruentzig AR: Transluminal dilatation of coronary artery stenosis. Lancet 1978; 1: 264
23. Thornton MA, Cruentzig AR, Hollman J, King III SB, Douglas JS: Coumadin and aspirin in the prevention of recurrence after transluminal coronary angioplasty: A randomized study. Circulation 1984; 69: 721-727
24. White CW, Knudson M, Schmidt D, et al: Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: results from a randomized placebo-controlled multicenter trial. (Abstract) Circulation 1987; 76: IV-213
25. Schwartz L, Bourassa MG, Lesperance J, et al: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719
26. Sekiguchi S, Morikawa A, Nakajima K, et al: Clinical usefulness of cilostazol (pletaal) on diabetic neuropathy and serum lipid levels. Jpn Pharmacol Ther 1991; 19: 291 -295 (in Japanese)
27. Tamai T, Shimada A, Maeda H, et al: Reduction of low density lipoprotein by cilostazol in the non-insulin dependent diabetic patients. Jpn Pharmacol Ther 1992; 20: 241 -248 (in Japanese)
28. Kamiya T, Sakaguchi S: Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung/Drug Res 1985; 35: 1201-1203
29. Ohashi S, Iwatani Y, Hyakuna Y, Morioka Y: Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung/Drug Res 1985; 35: 1203-1208
30. Shintani S, Watanabe K, Kawamura K, et al: General pharmacological properties of cilostazol, a new antithrombotic drug. Arzneimittelforschung /Drug Res 1985; 35: 1163-1172